Chem. J. Chinese Universities ›› 2010, Vol. 31 ›› Issue (12): 2413.

• Articles • Previous Articles     Next Articles

Synthesis and Biodistribution of  125I-DMAIBZM for Dopamine D2 Receptor Imaging

LI Guang-Hui, SHENG Xu-Jing, ZHU Jian-Hua*   

  1. School of Pharmacy, Fudan University, Shanghai 201203, China
  • Received:2010-02-09 Revised:2010-05-12 Online:2010-12-10 Published:2010-12-06
  • Contact: ZHU Jian-Hua E-mail:072103152@fudan.edu.cn
  • About author:朱建华, 男, 教授, 博士生导师, 主要从事放射性药物的研究.
  • Supported by:

    Major State Basic Research Development Program

Abstract: To improve the brain uptake of the benzamide compound 125I-AIBZM (S)- 5-125I -N-(1-ethyl-2-pyrrolidinyl) methyl-4-amine -2-methoxy- benzamide, the structure modification was performed resulting in a new compound 125I-DMAIBZM ((S)-5-125I-Iodo-N-(1-ethyl-2-pyrrolidinyl)methyl-4-dimethyl- amine-2-methoxy-benzamide) produced. Labeling was achieved by Iodogen method, with 74% radiochemical yield. After HPLC purification, radiochemical purity >99% was obtained. The receptor binding affinity of DMABZM to rat brain membrane(IC50为2.9589×10-7 mol?L-1)have shown high affinity to dopamine D2 receptor. The mice biodistribution data for 125I-DMAIBZM (the ratio striatum/cerebellum>6.5) indicates a good distribution in striatum with high specificity and affinity. The lipophilicity of 125I-DMAIBZM is significantly higher than that of 125I-AIBZM. Conclusion: 125I(123I)-DMAIBZM is in a promise state for Dopamine D2 receptor Imaging.

Key words: Dopamine D2 receptor, 125I;receptor imaging

TrendMD: